Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Migraine and Work-disability: How Treatment with Monoclonal Antibodies Against CGRP Pathway Could Reduce Work-related Burden Among Migraine Population.

NCT06812299 is registered in ClinicalTrials.gov with IRCCS National Neurological Institute "C. Mondino" Foundation as lead sponsor.

NCT NCT06812299
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06812299 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Migraine and Work-disability: How Treatment with Monoclonal Antibodies Against CGRP Pathway Could Reduce Work-related Burden Among Migraine Population.
Lead sponsor
IRCCS National Neurological Institute "C. Mondino" Foundation
Phase
Observational
Overall status
Completed
Start date
January 1, 2023
Completion date
November 1, 2024
Enrollment
175 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

headache (migraine)